POETYK PSO LTE study findings of deucravacitinib in plaque psoriasis: Leon Kircik
Touch Medical Media coverage of data presented at EADV 2023:
The POETYK PSO long term extension (LTE) study investigated the efficacy and safety of deucravacitinib at 3 years in patients with plaque psoriasis (NCT04036435).
touchDERMATOLOGY were delighted to speak with Dr. Leon. Kircik around the mechanism of action of deucravacitinib, the clinical data supporting its use in clinical practice, and the long term efficacy and safety data from the POETYK PSO LTE.
This information is provided solely by Touch Medical Media and is independent of any sponsorship or affiliation with the European Academy of Dermatology & Venereology (EADV).
Questions
- What is the mechanism of action of deucravacitinib? (0:21)
- What clinical evidence already supports the use of deucravacitinib? (0:41)
- What were the findings from the POETYK PSO long-term extension trial? (1:25)
- How will these insights optimise the use of deucravacitinib in plaque psoriasis? (2:10)
- In which patients is deucravacitinib most beneficial? (2:43)
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones and Katey Gabrysch.
Filmed in coverage of the EADV Annual Meeting.
This content was developed by Touch Medical Media and is not affiliated with the European Academy of Dermatology & Venereology (EADV) or the congress.
Click here for more content on psoriasis & for further EADV 2023 highlights visit here.
Disclosures:
Leon Kircik has the following disclosure information:
H = Honorarium; G = Grant
- Abbott Laboratories: Speaker (H)
- Abbvie: Consultant (H), Investigator (G)
- Ablynx: Investigator (G)
- Aclaris: Advisory Board (H)
- Acambis: Investigator (G)
- Allergan, Inc.: Investigator (H), Advisory Board (H), Speaker (H), Consultant (H)
- Almirall: Consultant (H), Investigator (G), Speaker (H), Advisory Board (H)
- Amgen, Inc.: Consultant (H), Investigator (G), Speaker (H), Advisory Board (H)
- Anacor Pharmaceuticals: Investigator (G), Consultant (H), Advisory Board (H)
- Anaptys: Investigator (G)
- Arcutis: Investigator (G), Advisory Board (H), Consultant (H)
- Arena: Investigator (G), Advisory Board (H)
- Assos Pharma: Speaker (H)
- Astellas Pharma US, Inc.: Investigator (G), Speaker (H)
- Asubio: Investigator (G)
- Bausch Health: Investigator (G)
- Berlex Laboratories (Bayer HealthCare Pharmaceuticals): Investigator (G)
- Biogen-Idec: Advisory Board (H)
- Biolife: Investigator (G)
- Biomimterix: Investigator (G)
- Biopelle: Investigator (G)
- BMS: Consultant (H), Investigator (G), Advisory Board (H)
- Boehringer-Ingleheim: Investigator (G)
- Breckinridge Pharma: Investigator (G)
- Cassiopea: Consultant (H), Advisory Board (H)
- Centocor, Inc.: Investigator (G)
- Cellceutix: Investigator (G)
- Cipher: Consultant (H), Speaker (H), Advisory Board (H)
- Coherus: Investigator (G)
- Colbar: Consultant (H), Advisory Board (H)
- Combinatrix: Investigator (G)
- Connetics Corporation: Advisory Board (H), Consultant (H), Speaker (H), Investigator (G)
- Coria: Investigator (G)
- Dermavant: Investigator (G), Consultant (H), Speaker (H), Advisory Board (H)
- Dermira: Investigator (G), Consultant (H), Speaker (H), Advisory Board (H)
- Dermik Laboratories: Speaker (H)
- Dow Pharmaceutical Sciences, Inc.: Investigator (G)
- Dr. Reddy’s Lab: Investigator (G), Consultant (H), Advisory Board (H)
- Dusa: Investigator (G)
- Embil Pharmaceuticals: Speaker (H)
- Eli Lilly: Investigator (G), Speaker (H), Advisory Board (H), Consultant (H)
- EOS: Advisory Board (H)
- Exeltis: Advisory Board (H), Consultant (H), Speaker (H), Investigator (G)
- Ferndale Laboratories, Inc.: Advisory Board (H), Investigator (G)
- Foamix: Investigator (G), Advisory Board (H)
- Ferrer: Consultant (H), Speaker (H)
- Galderma: Consultant (H), Speaker (H), Advisory Board (H), Investigator (G)
- Genentech, Inc.: Advisory Board (H), Speaker (H), Investigator (G), Consultant (H)
- GlaxoSmithKline, PLC: Investigator (G), Speaker (H), Consultant (H), Advisory Board (H)
- Glenmark: Investigator (G), Advisory Board (H)
- Health Point, LTD: Investigator (G)
- Idera: Investigator (G)
- Incyte: Investigator (G), Advisory Board (H)
- Intendis: Advisory Board (H), Consultant (H), Investigator (G)
- Innocutis: Speaker (H), Advisory Board (H)
- Innovail: Speaker (H)
- Isdin: Advisory Board (H), Consultant (H)
- Johnson & Johnson: Consultant (H), Investigator (G), Advisory Board (H), Speaker (H)
- Kyowakirin: Speaker (H)
- Laboratory Skin Care Inc.: Consultant (H)
- Leo: Investigator (G), Consultant (H), Speaker (H)
- L’Oreal: Investigator (G), Speaker (H)
- 3M: Speaker (H), Investigator (G)
- Maruho: Investigator (G)
- Medical International Technologies: Consultant (H)
- Merck: Consultant (H), Investigator (G)
- Medicis Pharmaceutical Corp.: Investigator (G)
- Merz: Consultant (H)
- Nano Bio: Advisory Board (H), Investigator (G)
- Nektar: Investigator (G)
- Nimbus: Investigator (G)
- Novartis AG: Investigator (G), Consultant (H), Speaker (H), Advisory Board (H)
- Noven Pharmaceuticals: Investigator (G)
- Nucryst Pharmaceuticals Corp: Investigator (G)
- Obagi: Investigator (G)
- Onset: Investigator (G), Speaker (H)
- OrthoNeutrogena: Speaker (H), Investigator (G), Advisory Board (H), Consultant (H)
- PediaPharma: Speaker (H)
- Pfizer: Investigator (G)
- Promius: Investigator (G), Consultant (H), Advisory Board (H)
- PuraCap: Consultant (H)
- PharmaDerm: Investigator (G), Speaker (H)
- QLT, Inc: Investigator (G)
- Quinnova: Investigator (G), Advisory Board (H)
- Quatrix: Investigator (G)
- Rapt: Investigator (G), Consultant (H)
- Regeneron: Investigator (G), Speaker (H)
- Sanofi: Speaker (H), Investigator (G), Consultant (H), Advisory Board (H)
- Serono (Merck Serono International SA): Speaker (H)
- SkinMedica, Inc.: Consultant (H), Investigator (G), Advisory Board (H), Speaker (H)
- Stiefel Laboratories, Inc.: Speaker (H), Investigator (G), Advisory Board (H), Consultant (H)
- Sun Pharma: Consultant (H), Advisory Board (H), Speaker (H), Investigator (G)
- Taro: Consultant/Speaker (H)
- TolerRx: Investigator (G)
- Triax: Speaker (H)
- UCB: Investigator (G), Consultant (H), Speaker (H)
- Valeant Pharmaceuticals Intl: Advisory Board (H), Investigator (G), Consultant (H), Speaker (H)
- Ventyx: Investigator
- Warner-Chilcott: Advisory Board (H), Speaker (H), Investigator (G)
- XenoPort: Investigator (G)
- ZAGE: Consultant (H)
